Topic: research and development
We started the Rotten Tomatoes special feature last year to spotlight companies that haven't followed through on the tough ethical and scientific demands of the biotech industry. This year, we’re at it again with a bit of a twist: We included companies bruised in 2016 but revived in 2017.
Vir Biotech CEO Geroge Scangos has lined up infectious disease and immunology expert Skip Virgin from Washington University as its new R&D head.
AstraZeneca doubles down on Chinese business through a new drug development joint venture with a state-backed private equity firm.
The U.K. government announced that former GlaxoSmithKline chief Sir Andrew Witty will head up new pathway to get med and tech onto the market quicker.
Indivumed and Helomics have teamed up to advance research in personalized cancer treatments.